- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00174681
Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
Primary objective:
The primary objective of this trial is:
- To evaluate the efficacy of initiating Lantus in combination with oral antidiabetics drugs compared to oral antidiabetic treatment optimised by enhancing hygienic and dietary measures in type 2 diabetics whose blood glucose control is acceptable but not optimal on maximum oral treatment, based on the number of patients achieving a HbA1c value < 7% at the end of treatment.
Secondary objectives:
The secondary objectives of this trial are to compare between the two treatment groups:
- The variation in HbA1c between baseline and end of trial.
- The frequency of episodes of symptomatic hypoglycaemia (diurnal and nocturnal), severe hypoglycaemia (diurnal and nocturnal) and asymptomatic hypoglycaemia.
- Mean blood glucose levels at different times of the day.
- The variation in weight and lipid in each group between baseline and end of trial.
- The incidence of adverse events.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Zagreb, Croatia
- Sanofi-Aventis
-
-
-
-
-
Prague, Czech Republic
- Sanofi-Aventis
-
-
-
-
-
Paris, France
- Sanofi-Aventis
-
-
-
-
-
Bucharest, Romania
- Sanofi-Aventis
-
-
-
-
-
Moscow, Russian Federation
- Sanofi-Aventis
-
-
-
-
-
Ljubljana, Slovenia
- Sanofi-Aventis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
Subjects fulfilling all of the following criteria will be eligible for inclusion in the trial:
- Type 2 diabetes
- 24 ≤ BMI ≤ 35 kg/m2
- 7 % ≤ HbA1c ≤ 8 %
- Treated with OAD for at least 2 years
- Treated with at least two oral antidiabetics including one sulphonylurea at the maximum tolerated dosages and metformin at the maximum tolerated dosages
- Not treated with a glinide or thiazolidinedione.
- Capable of performing blood glucose self-monitoring and a self-injection of insulin.
- Funduscopy within the previous year at the time of inclusion.
Exclusion Criteria:
Patient with any of the following criteria will not be included in the trial:
- Type 1 diabetics
- Insulin-treated type 2 diabetics or having previously received long-term insulin, or treated with a thiazolidinedione or glinide
- Fasting blood glucose < 1.20 g/l.
- Pregnancy (non-menopausal women must have a pregnancy test before the inclusion visit and effective contraception).
- Lactation.
- History of hypersensitivity to the investigational product or to drugs with similar chemical structures.
- Systemic treatment with corticosteroids irrespective of the dose and irrespective of the previous or anticipated duration of treatment.
- Treatment with another product under development in the 2 months preceding the date of inclusion in the study.
- Subject likely to receive treatments prohibited in the protocol during the trial.
- Cardiovascular, hepatic, neurological, endocrine or any other disease making it difficult to carry out the protocol or interpret the results.
- Proliferative or rapidly progressive or unstable retinopathy for at least 6 months after treatment by surgery or laser, or requiring surgery or laser in the 3 months following inclusion in the study.
- Hepatic impairment:ALT and/or AST more than three times the upper limit of normal at the initial assessment.
- Renal insufficiency:Serum creatinine >177 µmol/l (>20 mg/l) or creatinine clearance <60 ml/min.
- Previous or current history of alcohol or drug abuse.
- Mental state rendering the subject incapable of understanding the nature, objectives and possible consequences of the trial.
- Inability to undertake blood glucose self-monitoring and the injection of insulin alone.
- Subject unable to accept the restrictions of the protocol (uncooperative, unable to attend the follow-up visits and probably incapable of completing the trial).
- Subjects deprived of freedom by an administrative or judicial decision.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Percentage of subjects achieving HbA1c < 7% at the end of the study.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HOE901_4042
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Insulin Glargine
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
-
SanofiCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
SanofiCompletedDiabetes Mellitus Type 2Germany
-
University of AarhusCompletedDiabetes Mellitus, Type 1Denmark
-
IRCCS San RaffaeleTerminatedType 2 Diabetes Mellitus | Peripheral Vascular DiseaseItaly
-
SanofiCompleted
-
Johns Hopkins UniversityTerminatedHypoglycemia | Type 1 DiabetesUnited States
-
Medical University of GrazCompletedDiabetes Mellitus, Type 2Austria
-
SanofiCompletedType 1 Diabetes MellitusJapan